Zhengye Biotechnology's Recent NASDAQ Notice
Recently, Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT), a leading veterinary vaccine manufacturer based in China, received a notice from the NASDAQ Stock Market regarding a compliance issue. The notice was sent to the company concerning its failure to timely file the Form 20-F for the fiscal year ending December 31, 2024.
Understanding the Delinquency Letter
This notification, known as the 'Delinquency Letter,' highlights that Zhengye Biotechnology has not adhered to the NASDAQ Listing Rules, specifically Rule 5250(c)(1). This rule mandates companies to submit their annual reports promptly to ensure transparency and regulatory compliance.
According to the guidelines provided in the Delinquency Letter, the Company has a window of 60 calendar days to develop a plan to regain compliance, referred to as the Compliance Plan. This is a crucial step for Zhengye to maintain its listing status on the NASDAQ, which is essential for its investors and ongoing operations.
Path to Compliance
Should NASDAQ approve Zhengye's Compliance Plan, the Company might receive an extension of up to 180 days to rectify this filing issue. This extension could allow the company until November 11, 2025, to fulfill its obligations regarding the Form 20-F filing.
Despite this setback, it is worth noting that the Delinquency Letter does not immediately jeopardize the listing status of the company’s ordinary shares on the NASDAQ Capital Market. Zhengye remains committed to addressing the concerns outlined in the letter and aims to submit their Compliance Plan within the stipulated timeframe.
About Zhengye Biotechnology Holding Limited
Zhengye Biotechnology, through its operating entity, Jilin Zhengye Biological Products Co., Ltd., focuses heavily on the research and development of veterinary vaccines. This commitment has positioned Zhengye as a key player in the industry, particularly in providing vaccines tailored for livestock across China.
Company Operations and Product Range
For more than two decades, Zhengye Biotechnology has dedicated its efforts to improving animal health and welfare through innovative vaccine solutions. The company boasts a diverse range of 44 veterinary vaccines designed for various species including swine, cattle, goats, sheep, poultry, and dogs.
These products are not only distributed across 28 provinces in China but also exported to international markets such as Vietnam, Pakistan, and Egypt. With three GMP-certified production floors and 13 GMP vaccine production lines, Zhengye maintains stringent quality standards and controls in its operations.
Expertise and Workforce
The company employs a skilled workforce of 49 individuals, all possessing over ten years of experience in the veterinary vaccine industry. This knowledgeable team is pivotal in driving Zhengye’s research and development initiatives, ensuring that they remain at the forefront of veterinary medicine.
Contact Information for Zhengye Biotechnology
For those looking for more information or wishing to reach out regarding investor relations, Zhengye Biotechnology Holding Limited provides dedicated contact options:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
Frequently Asked Questions
What triggered the NASDAQ notice to Zhengye Biotechnology?
The notice was issued due to Zhengye not filing its Form 20-F on time, violating NASDAQ Listing Rule 5250(c)(1).
What is the timeframe for Zhengye to respond to the NASDAQ notice?
Zhengye has 60 calendar days from receiving the notice to submit its Compliance Plan.
Will the company's listing on NASDAQ be affected immediately?
No, the notice does not have an immediate impact on the company’s listing status.
What types of products does Zhengye Biotechnology offer?
Zhengye offers a range of 44 veterinary vaccines for various livestock and pets.
How can investors reach Zhengye Biotechnology for inquiries?
Investors can contact the Investor Relations Department via email at ir@jlzybio.com.
